Related Experiment Videos
HAART patients can face greater risk of developing heart disease--studies
AIDS Alert
|February 28, 2002
Insights
Human immunodeficiency virus (HIV) patients taking protease inhibitors showed a higher rate of myocardial infarctions. This finding highlights potential cardiovascular risks associated with long-term HIV treatment.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- Protease inhibitors are a key component of highly active antiretroviral therapy (HAART) for HIV.
- Long-term effects of HAART on cardiovascular health require ongoing investigation.
Framework:
- The HIV Outpatient Study (HOPS) is a multi-site observational cohort study.
- Data were collected from 10 sites across the United States.
Implementation:
- The study analyzed data from HIV patients undergoing treatment with protease inhibitors.
- Researchers observed patient outcomes over several years of treatment.
Implications:
- Findings suggest a potential link between protease inhibitor use and increased myocardial infarction risk in HIV patients.
- This highlights the need for cardiovascular risk assessment and management in patients on long-term HIV therapy.
- Further research is warranted to elucidate the mechanisms behind this association.
Abstract:
Investigators from the HIV Outpatient Study group, which is located at 10 sites in the United States, found that after a few years of taking protease inhibitors, HIV patients were beginning to show a significantly increased rate of myocardial infarctions. The researchers presented their findings at the 2001 IDSA Conference, held Oct. 25-28, 2001.